Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	16.15B -40.2%
Revenue (ttm)	31.42M -27.9%
Net Income	-356.04M
EPS	-2.14
Shares Out	167.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,744
Open	96.40
Previous Close	96.40
Day's Range	95.40 - 96.90
52-Week Range	93.80 - 329.50
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors. In addition, the compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 36
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2025, Lumosa Therapeutics's revenue was 35.83 million, a decrease of -8.49% compared to the previous year's 39.15 million. Losses were -340.54 million, -19.83% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 16, 2026

Data Sources Report a data error